Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "BRCA" Condition: Ovarian Cancer Clear all
Not listed No phase listed Observational

Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

NCT03691012
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Circulating tumour DNA testing
Diagnostic Test
Lead sponsor
Walter and Eliza Hall Institute of Medical Research
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

NCT03824704
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma, Endometrioid Adenocarcinoma
Interventions
Rucaparib, Nivolumab
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Clovis, California • Savannah, Georgia • Covington, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation

NCT02477202
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Mirena® intra-uterine device (IUD)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 1 Interventional

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT04890613
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CX-5461
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhance the Use of Genetic Counseling and Testing in Latinas

NCT04544501
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer Syndrome
Interventions
Culturally-Targeted Video, FORCE Fact Sheet
Behavioral · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia • Arlington, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer

NCT06436248
View directory record Official record
Conditions
Ovarian Cancer, BRCA Mutation
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
25 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Phase II ABT-888 With Cyclophosphamide

NCT01306032
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions
ABT-888, Cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Davis, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT04606914
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Interventions
mirvetuximab soravtansine (MIRV; IMGN853)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

NCT02571725
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Olaparib, Tremelimumab
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Albuquerque, New Mexico • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jul 23, 2026, 4:15 PM EDT
Active, not recruiting Phase 1 Interventional

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678
View directory record Official record
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Not applicable Interventional Results available

Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

NCT03606486
View directory record Official record
Conditions
High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Lavage, Pap Smear
Other · Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Not listed No phase listed Observational

Increase Surveillance for Breast and Ovarian Cancers, Also to Determine Targeted Risk-reducing and Preventative Strategies

NCT03319290
View directory record Official record
Conditions
Hereditary Cancer
Interventions
BRCA1 and BRCA2
Genetic
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
18 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

NCT02983799
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

NCT04377087
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib
Drug
Lead sponsor
Sarah E Taylor
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

NCT00165152
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Genetic Counseling, Informed Consent Counseling
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Jul 23, 2026, 4:15 PM EDT
Active, not recruiting Phase 3 Interventional

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Boca Raton, Florida • Towson, Maryland • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed No phase listed Observational

Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer

NCT02406235
View directory record Official record
Conditions
Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
San Francisco, California • Gainesville, Florida • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 1 Interventional

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

NCT06856499
View directory record Official record
Conditions
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Cirtuvivint, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 1 Interventional

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

NCT03944902
View directory record Official record
Conditions
Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
Interventions
Cohort 1: Dose Escalation, Cohort 2: Dose Escalation
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting No phase listed Observational

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774
View directory record Official record
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Interventions
Clinical Trial Matching
Other
Lead sponsor
Massive Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

NCT04503265
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions
AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
Drug
Lead sponsor
AtlasMedx, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00677079
View directory record Official record
Conditions
Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer
Interventions
Iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Jul 23, 2026, 4:15 PM EDT
Enrolling by invitation Not applicable Interventional

Genetic Education in BRCA Families

NCT03544983
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Web + Streamlined Telephone Genetic Information
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 23, 2026, 4:15 PM EDT